

Creativity. Capability. Capital.

AusBiotech2011
AUSTRALIA'S BIOTECHNOLOGY CONFERENCE



16 to 19 October 2011
Adelaide Convention Centre, South Australia
www.ausbiotech2011.com.au



AUSBIOTECH 2011 CONFERENCE SPEAKERS' PROFILE

Dr Peter French
CEO
Benitec Limited, Australia

Dr Peter French is the Chief Executive Officer and Chief Scientific Officer of Benitec Ltd. He has an MBA in Technology Management and a PhD in cell and molecular biology, and extensive experience in medical research and biotechnology spanning 33 years.

He was Principal Scientist at St Vincent's Hospital Centre for Immunology for 15 years until 2002, and founded publicly listed company Cryosite in 1999.

Peter is a Conjoint Senior Lecturer at the University of New South Wales and Honorary Fellow at Macquarie University.

He is a Past President of the Australia and New Zealand Society for Cell and Developmental Biology, is a current member of the Board of the International Society for Differentiation.

Contact Details:

Benitec Ltd
F6A / 1-15 Barr Street,
Balmain NSW 2041
Australia
Website: www.benitec.com
Office: +61 (0)2 9555 6986
Email: pfrench@benitec.com



About Benitec

Benitec Limited is a publicly listed (ASX:BLT) biotechnology company developing novel treatments for chronic and life-threatening conditions based on a transformational gene silencing technology, DNA-directed RNA interference (ddRNAi). Benitec holds the predominant patent position in the use of ddRNAi for human therapeutic and research applications. The key asset is an exclusive, irrevocable and world-wide license to CSIRO's patent estate covering methods for silencing genes by generating double stranded RNA inside a cell from a DNA construct. Benitec is collaborating with organisations globally to utilise its patent estate to develop novel therapeutics for chronic life threatening diseases and disorders, particularly in cancer and infectious disease. Benitec's current projects are directed to using gene silencing to overcome drug resistance in lung cancer, to provide a novel solution to intractable cancer-associated pain, and to develop a cure for chronic hepatitis B infection.